How to Foster the Next Innovation in Oncology Clinical Development and Medical Affairs Strategy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post by Shravika K, Program Coordinator at Inovine conferences, on LinkedIn, adding:
“Glad to present on critical elements driving successful innovation in Oncology drug development. Will be contrasting approaches to small molecules, Abs and cell therapy across clinical development and medical affairs with optimal positioning for interaction with regulatory and health authorities.
Highlights will include incorporation of latest FDA guidances on dose optimization as well as global regulatory and patient access implications. Join the productive exchange at the 10th International Cancer Congress!”
Quoting Shravika K‘s post:
“Join us at the conference for a talk by Tanja Obradovic on “How to Foster the Next Wave of Innovation in Oncology Clinical Development and Medical Affairs Strategy.”
This session will explore cutting-edge strategies and insights essential for advancing oncology research and practice. Don’t miss the opportunity to learn from one of the leading experts in the field.”
Click here to register and to join the conference.
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023